Verition Fund Management 13F: New $16M Stake in APLS
Verition Fund Management disclosed a brand-new holding in Apellis Pharmaceuticals, Inc. NGM:APLS during the recent reporting period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Verition Fund Management opened a new position of 400,000 shares in Apellis Pharmaceuticals, Inc. ($APLS), according to a 13F filing with the SEC dated May 15, 2026. It reported 400,000 shares worth $16.41 million at the end of the quarter.
Find the original: Verition Fund Management 13F filings on SEC EDGAR
Key Points
- Verition Fund Management initiated a new stake in Apellis Pharmaceuticals, Inc. NGM:APLS by acquiring 400000 shares.
- Verition Fund Management held 400,000 $APLS shares at quarter end, all of it a new position.
- The newly established holding carried a reported value of approximately $16.4 million based on the filing details.
- Apellis Pharmaceuticals shares trade near $41.03, sitting right below the 52-week high of $41.14.
Get $APLS trade alerts by text
We text you when insiders, Congress or big funds trade $APLS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apellis Pharmaceuticals, Inc. alert may contain errors. Disclosures
Verition Fund Management Initiates Position in Apellis Pharmaceuticals
Verition Fund Management took a new stake in Apellis Pharmaceuticals, Inc. NGM:APLS during the period ended May 15, 2026. According to a Form 13F filed with the Securities and Exchange Commission, the fund added 400000 shares to its portfolio. The newly initiated holding carried a reported value of about $16.4 million.
Inside the New Apellis Holdings
The filing shows that Verition Fund Management bought 400000 shares to build its position from scratch. Because the investor held zero shares previously, this action represents a brand-new position rather than an adjustment to an existing holding. The reported cost basis sits at $29.68 per share, while the total value of the purchase reached $16412000.0.
Apellis Stock Trades Near Yearly Highs
Shares of Apellis Pharmaceuticals changed hands around $41.03 recently, sitting close to the company's 52-week high of $41.14. The biotechnology equity trades well above its 50-day moving average of $33.60 and its 200-day moving average of $26.15. This strong price momentum places the stock near the top end of its 52-week range, which started as low as $16.61.
Inside the Business
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical enterprise based in Waltham, Massachusetts, that builds treatments for conditions with high unmet medical needs. The firm develops therapies such as Empaveli and Syfovre to address specific blood and eye disorders. Institutional investors regularly review these drug pipelines as the company advances its clinical research programs.
What to Watch at Apellis Pharmaceuticals, Inc.
Because 13F filings look backward at portfolio holdings from a specific date, this position might not reflect the fund's current share count today. Market participants will need to wait for subsequent quarterly disclosures to see whether the fund builds upon this initial stake. The next round of SEC filings and corporate updates will provide a clearer picture of institutional sentiment moving forward.
Related Filing Alerts
Source: Verition Fund Management's 13F filing on $APLS (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Verition Fund Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts